Japanese guidelines for allergic rhinitis 2017

Okubo, Kimihiro; Kurono, Yuichi; Ichimura, Keiichi; Enomoto, Tadao; Okamoto, Yoshitaka; Kawauchi, Hideyuki; Suzaki, Harumi; Fujieda, Shigeharu; Masuyama, Keisuke

doi:10.1016/j.alit.2016.11.001

Cited by 198 publications

(209 citation statements)

References 15 publications

Supporting

Mentioning

200

Contrasting

Unclassified

Order By: Relevance

“…Diagnosis is usually confirmed by assessing patient history, reaction to contact with known allergens, seasonal history of rhinitis through skin prick test and detection of specific IgE antibodies in the patient's blood serum where treatment is usually administered as per standard guidelines published in each country [15,16].…”

Section: Discussionmentioning

confidence: 99%

A New Class of Polymeric Anti-Allergen Nasal Barrier Film Solution for the Treatment of Allergic Rhinitis

Shrivastava¹,

Schütte²,

Malik³

et al. 2017

J Allergy Ther

View full text Add to dashboard Cite

Objective: Allergic rhinitis (AR) is oversensitivity of nasal mucosa to allergen exposure leading to IgE-mediated nasal mucosal inflammation and cellular destruction. Applying any chemical drug over the nasal mucosa may provide symptomatic relief but at the same time the presence of chemicals, such as cortisones and antihistaminic, hampers mucosa repair and, in consequence, cellular defense functions. Therefore, cleaning, avoiding allergen exposure, and protecting nasal mucosa from contact with allergens with a cell-friendly mechanical device, could be an effective remedy to treat allergic rhinitis. Methods:A double blind, randomized, placebo controlled, multicenter clinical trial was conducted in patients suffering from severe AR. 15 patients were treated with saline as comparator product (CP) versus 31 treated with the test product (TP). The test product contained a natural gum-glycerol solution (VB-Gy) which was rendered filmogen using inert natural polymers (Allercyanidin-H) and termed as VB-Gy-Allercyanidin-H formula. The products (15 ml sprays) were applied topically over the nasal mucosa, 3-4 times a day over a period of 3 weeks. Total, reflective and instantaneous nasal symptom scores for rhinorrhea, nasal discharge, sneezing, and itching, as well as ocular scores (itching, tearing, redness) and rescue medicine use scores were evaluated daily during weeks -1 to +3 employing a 0 (no symptoms) to 3 (severe symptoms) scoring scale. Rhino-conjunctivitis quality of life (RQLQ) questionnaires were completed at the start and at the end of the study. Saline solution (CP) was used identically to the TP. Mean weekly results in CP and TP groups were compared with the scores at the start of treatment (baseline) and between the two groups.Results: CP was found to reduce only slightly the symptomatic manifestation of allergic rhinitis. The mean reduction compared to baseline at the end of weeks 1, 2, and 3 was respectively 11.7%, 13.6% and 15.1% for total nasal symptom scores (rTNSS); 9.9%, 14.5%, and 15.8% for total ocular symptom scores (rTOSS); and 4.97%, 8.45%, and 10.94% for pre-dose instantaneous total ocular symptom scores (am-iTOSS, p: Not Significant: NS). During the same period, compared to CP scores, the reduction in TP group was higher by 37.7%, 58.4%, and 73.5% for rTNSS; 38.3%, 54.6%, and 64.1% for rTOSS and 29.84%, 48.91%, and 59.77% for am-iTOSS (p<0.05 for all parameters vs. CP at the same time points). The rhinoconjunctivitis quality of life questionnaire (RQLQ), measured using standard established questionnaire, was improved by 50.28% in TP group compared to 22.85% in CP group. During the study period, at least one rescue medicine was used by 80% patients in CP group compared to only 29% in TP group. Both products were well tolerated and induced no undesired effects. Conclusion:In the absence of any cell-friendly, safe, and multi-target treatment for allergic rhinitis, using a mechanically acting, filmogen barrier solution capable of blocking new allergen contact and minimizing the concentra...

show abstract

Section: Discussionmentioning

confidence: 99%

A New Class of Polymeric Anti-Allergen Nasal Barrier Film Solution for the Treatment of Allergic Rhinitis

Shrivastava¹,

Schütte²,

Malik³

et al. 2017

J Allergy Ther

View full text Add to dashboard Cite

show abstract

“…Indeed, if possible the patients should be chosen prudently to avoid serious adverse reactions. The major contraindications of SIT (SCIT and SLIT), however, are as the follows (73,124,129):…”

Section: Contraindicationsmentioning

confidence: 99%

Chinese Guideline on allergen immunotherapy for allergic rhinitis

et al. 2017

View full text Add to dashboard Cite

“…Suppurative and allergic inflammation is particularly common. Various medications have been developed to prevent or reduce the symptom of AR such as corticosteroids, antihistamines, decongestants, anticholinergics and leukotriene receptor antagonists [3]. However, permanent curative medicines for AR have not been established yet.…”

Section: Introductionmentioning

confidence: 99%